Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update March 31, 2025 4:00 PM EDT | Source: Phio Pharmaceuticals Corp. Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing te ...